INmune Bio files CORDStrom patent in U.S. after favorable PCT opinion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 1, 2026 7:00 AM EDTSecures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
BOCA RATON, Fla., July 01, 2026 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the Company), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its CORDStrom platform patent application into the U.S. national phase before the United States Patent and Trademark Office (USPTO), advancing a key element of the Companys global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC)... More
